Moderna released the latest data on mRNA vaccines: the level of neutralizing antibodies in the booster needle increased by 83 times

Article source: Medical Rubik's Cube Info

Author: Shi Bei

On December 20, Moderna announced the preliminary neutralizing antibody data of the mRNA new crown vaccine (elasomeran, mRNA-1273) at 50 µg and 100 µg doses against the Omicron variant

As mentioned before, Moderna is constantly advancing the booster vaccine to deal with the emerging mutants of concern (VOC)

The data disclosed on December 21 included sera from 20 booster vaccinators, including subjects vaccinated with mRNA-1273 (50µg and 100µg) booster, vaccinated with multivalent candidate vaccine mRNA-1273.

Before the booster shot, all groups had low levels of neutralizing antibodies to Omicron

Moderna also announced the safety and tolerability data of the Phase II/III study of a 100µg dose of mRNA-1273 (N=305) booster

Given the strength of mRNA-1273 and the propagation speed of Omicron variants, Moderna’s first line of defense against Omicron will be mRNA-1273 booster vaccination

On December 15th, Pfizer and BioNTech jointly announced that one month after receiving the booster vaccination (the third dose of BNT162b2 vaccine), the serum obtained from the vaccinee can neutralize the Omicron variant, and the neutralization level is the same as that of 2 doses.